Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
International Journal of Organ Transplantation Medicine. 2011; 2 (1): 1-3
em Inglês | IMEMR | ID: emr-110834
2.
Journal of the Faculty of Medicine-Shaheed Beheshti University of Medical Sciences and Health Services. 2007; 31 (2): 109-116
em Persa | IMEMR | ID: emr-83705

RESUMO

Inflammation and oxidative stress are common in patients with chronic renal disease, including hemodialysis patients. The present study was designed to investigate the effects of L-carnitine supplements on inflammatory cytokines, CRP and oxidative stress in hemodialysis patients. The study was a randomized clinical trial. Thirty-six hemodialysis patients, [23 males and 13 females], were randomly assigned to either carnitine group or the control group. The patients in the carnitine group received 1000 mg/d oral L-carnitine for 12 weeks while the control group did not receive any L-carnitine supplement during the study. At the baseline and the end of 12th week of the study, 5 ml. blood was collected after a 12 to 14-hour fast from each patient before dialysis and then serum free carnitine, CRP, IL-1beta, IL-6, TNF-alpha and ox-LDL were measured. Mean serum free carnitine concentration increased significantly, by 86%, in the carnitine group at the end of 12th week as compared to the baseline [P<0.001], while serum CRP and IL-6 decreased significantly, by 29% [P<0.05] and 61% [P<0.001], respectively. No significant changes were observed in the serum concentrations of free carnitine, CRP and IL-6 in the control group during the study. There were no significant differences between mean changes of serum IL-1beta, TNF-alpha and ox-LDL concentrations in the two groups. This study indicated that L-carnitine supplement could improve carnitine deficiency and decrease inflammatory markers of CRP and IL-6 in hemodialysis patients


Assuntos
Humanos , Masculino , Feminino , Carnitina/deficiência , Diálise Renal/efeitos adversos , Interleucina-6/sangue , Estresse Oxidativo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA